Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Alzheimer disease and Down syndrome: factors in pathogenesis.

Lott IT, Head E.

Neurobiol Aging. 2005 Mar;26(3):383-9. Review.

PMID:
15639317
2.

Increased amyloid beta protein levels in children and adolescents with Down syndrome.

Mehta PD, Capone G, Jewell A, Freedland RL.

J Neurol Sci. 2007 Mar 15;254(1-2):22-7.

PMID:
17275850
3.

Developmental origins of aging in brain and blood vessels: an overview.

Finch CE.

Neurobiol Aging. 2005 Mar;26(3):281-91. Review.

PMID:
15639305
4.
5.

Down syndrome and Alzheimer's disease: a link between development and aging.

Lott IT, Head E.

Ment Retard Dev Disabil Res Rev. 2001;7(3):172-8. Review.

PMID:
11553933
6.
7.

Reduced short latency afferent inhibition in patients with Down syndrome and Alzheimer-type dementia.

Nardone R, Marth R, Ausserer H, Bratti A, Tezzon F.

Clin Neurophysiol. 2006 Oct;117(10):2204-10.

PMID:
16931146
8.
9.

Increased serum neopterin levels in adults with Down syndrome.

Mehta PD, Patrick BA, Dalton AJ, Patel B, Mehta SP, Pirttila T, Coyle PK.

J Neuroimmunol. 2005 Jul;164(1-2):129-33.

PMID:
15908015
10.

Down syndrome, Alzheimer's disease and seizures.

Menéndez M.

Brain Dev. 2005 Jun;27(4):246-52. Review.

PMID:
15862185
11.

Total serum cholesterol levels and Alzheimer's dementia in patients with Down syndrome.

Prasher VP, Airuehia E, Patel A, Haque MS.

Int J Geriatr Psychiatry. 2008 Sep;23(9):937-42. doi: 10.1002/gps.2014.

PMID:
18395888
12.

Apolipoprotein E, amyloid-beta, and blood-brain barrier permeability in Alzheimer disease.

Donahue JE, Johanson CE.

J Neuropathol Exp Neurol. 2008 Apr;67(4):261-70. doi: 10.1097/NEN.0b013e31816a0dc8. Review. Erratum in: J Neuropathol Exp Neurol. 2008 Jun;67(6):634.

PMID:
18379441
13.

Amyloid beta concentrations in older people with Down syndrome and dementia.

Jones EL, Hanney M, Francis PT, Ballard CG.

Neurosci Lett. 2009 Feb 20;451(2):162-4. doi: 10.1016/j.neulet.2008.12.030.

PMID:
19111900
14.

Apolipoprotein E, amyloid, and Alzheimer disease.

Bales KR, Dodart JC, DeMattos RB, Holtzman DM, Paul SM.

Mol Interv. 2002 Oct;2(6):363-75, 339. Review.

PMID:
14993413
15.

Greasing the wheels of Abeta clearance in Alzheimer's disease: the role of lipids and apolipoprotein E.

Fan J, Donkin J, Wellington C.

Biofactors. 2009 May-Jun;35(3):239-48. doi: 10.1002/biof.37. Review.

PMID:
19472365
16.

Why lipids are important for Alzheimer disease?

Hirsch-Reinshagen V, Burgess BL, Wellington CL.

Mol Cell Biochem. 2009 Jun;326(1-2):121-9. doi: 10.1007/s11010-008-0012-2.

PMID:
19116777
17.

Cerebral small vessel disease-induced apolipoprotein E leakage is associated with Alzheimer disease and the accumulation of amyloid beta-protein in perivascular astrocytes.

Utter S, Tamboli IY, Walter J, Upadhaya AR, Birkenmeier G, Pietrzik CU, Ghebremedhin E, Thal DR.

J Neuropathol Exp Neurol. 2008 Sep;67(9):842-56. doi: 10.1097/NEN.0b013e3181836a71.

PMID:
18716559
18.

Mortality is associated with apolipoprotein E epsilon4 in nondemented adults with Down syndrome.

Zigman WB, Jenkins EC, Tycko B, Schupf N, Silverman W.

Neurosci Lett. 2005 Dec 23;390(2):93-7.

PMID:
16122874
19.

Inflammation, genes and zinc in Alzheimer's disease.

Vasto S, Candore G, Listì F, Balistreri CR, Colonna-Romano G, Malavolta M, Lio D, Nuzzo D, Mocchegiani E, Di Bona D, Caruso C.

Brain Res Rev. 2008 Jun;58(1):96-105. doi: 10.1016/j.brainresrev.2007.12.001. Review.

PMID:
18190968
20.

Current insights into molecular mechanisms of Alzheimer disease and their implications for therapeutic approaches.

Van Broeck B, Van Broeckhoven C, Kumar-Singh S.

Neurodegener Dis. 2007;4(5):349-65. Review.

PMID:
17622778

Supplemental Content

Support Center